CooperVision Canada Marks Fifth Year of Raising Awareness About Childhood Myopia and Treatment Options

About this update from The Cooper Companies, Inc.

TORONTO , Aug. 18, 2025 /CNW/ - For the fifth year in a row, CooperVision Canada is investing in educating parents and raising awareness about myopia (aka nearsightedness) in children, emphasizing that it is more than just a blurry vision issue, it is a progressive condition that requires proactive management to help protect long-term eye health and preserve future opportunities for children. MiSight ® 1 day contact lenses from CooperVision can help age-appropriate children with myopia reach their full potential. MiSight ® 1 day is the first and only FDA approved* soft contact lens proven to slow the progression of myopia in children aged 8-12 at the initiation of treatment. 1† Myopia, or nearsightedness, is a common condition where distant objects appear blurry while close-up vision remains clear. It often develops during childhood, typically beginning in the early school years. 2-3 A 2018 study from the University of Waterloo found that 6% of children aged 6-8 had myopia, and this rate jumped to almost 30% for children aged 11-13, 4 highlighting the urgency for early intervention. Research suggests that increased screen time is contributing to the rise in myopia, 5 and studies have shown that spending more time outdoors may prevent or delay the onset of this eye condition. 6 MiSight ® 1 day contact lenses are designed to be part of a proactive myopia management treatment plan, 1† providing freedom from glasses and slowing the worsening of myopia 1† during a child's most critical years of growth. "When children develop myopia at a younger age, their condition tends to worsen more rapidly into their late teens, 7 which increases their risk of sight-threatening eye health conditions later in life, 8 " said Teresa Yu , Senior Manager of Marketing, CooperVision Canada. "We remain committed to helping parents understand that myopia is not just a blurry distance vision problem to correct with regular glasses or contact lenses, but a disease that needs to be treated and managed as early as possible. For five years, our direct-to-consumer campaign has focused on educating Canadian families about these critical issues." August is Children's Eye Health and Safety Month, and as part of CooperVision Canada's continual investment and commitment to children's eye health, this back-to-school season they are urging parents to proactively schedule regular eye exams for their children and talk to their eye care professionals about myopia management treatment options. MiSight ® 1 day is a safe, 9 convenient, single-use contact lens that doesn't require cleaning, solutions, or storage so children can start each day with a comfortable, fresh pair of lenses. MiSight ® 1 day is also uniquely backed by a multi-year, peer-reviewed clinical study that demonstrated sustained slowing of myopia progression in children who wore the lenses daily, compared to those wearing single-vision lenses. 1,10-13 The results showed not only significant slowing of eye length growth 1† but also excellent vision correction 1,10± and high satisfaction among young wearers and their parents. 14≠ Over a 3-year period, MiSight ® 1 day contact lenses slowed myopia progression by 59% on average. 1† Parent-approved MiSight ® 1 day contact lenses saw 90% of parents whose children wore the lenses report that their children were extremely happy 14≠ wearing MiSight ® 1 day lenses and strongly preferred them over their glasses. 15 MiSight ® 1 day contact lenses are available through licensed Canadian eye care professionals. To learn more about myopia and MiSight ® 1 day, visit   fightmyopia.ca . About CooperVision CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges, such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas, and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit   www.coopervision.ca . About CooperCompanies CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women's health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif. , CooperCompanies has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit   www.coopercos.com . SOURCE CooperVision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2025/18/c6902.html

View stock analysis, news, and events for The Cooper Companies, Inc.